See the DrugPatentWatch profile for berotralstat
What does US11117867B2 cover (berotralstat)?
US11117867B2 is a U.S. patent listed on Google Patents in connection with berotralstat, a hereditary angioedema (HAE) treatment. To interpret what the patent actually claims, you need to look at the document’s claim set and assignee on Google Patents (Google Patents organizes these directly under the patent page). [1]
What claims should you check on the Google Patents page?
On the Google Patents entry for US11117867B2, the most important sections for “what it covers” are typically:
- The independent claims (usually “1.” and other independent claim numbers), because they define the protected subject matter.
- Dependent claims, which narrow the invention with specific dosage/regimen/formulation details.
- The assignee/applicant and title/abstract fields, which help identify who filed the patent and the invention’s scope. [1]
Who owns US11117867B2 on Google Patents?
Google Patents shows the applicant/assignee for US11117867B2 on the patent’s main page and often lists related family members. That ownership is the key starting point for tracking enforcement, licensing, and whether other companies are challenging the same patent space. [1]
Is US11117867B2 part of the berotralstat patent family or exclusivity strategy?
Google Patents links patents into families (through priority claims). If US11117867B2 belongs to the same family as other berotralstat patents, you can use the “Patent family” / “Related documents” view to find:
- Corresponding filings in other countries
- Continuations/divisionals
- Closely related dosage/formulation/regimen patents [1]
When would US11117867B2 expire?
The expiry date depends on the patent’s key dates shown on Google Patents, such as filing date and any term adjustments. Google Patents provides the relevant timeline information on the patent page; you would use that to estimate the last enforceable date (and then compare it with market exclusivity rules if you’re doing an exclusivity mapping). [1]
Are other berotralstat patents likely to matter for generic/biosimilar entry?
Even if US11117867B2 is central, other patents in the berotralstat family (or listed in relevant regulatory exclusivity/Orange Book-style listings, if applicable) can control when a competitor can market a competing product without infringement risk. The practical approach is to compile:
- All relevant berotralstat patents around dosing/regimens and formulations
- Any related continuations/divisionals
- Any later patents that may have overlapping claim scope [1]
What to search next on Google Patents if you want the exact invention wording
From the US11117867B2 page, search within the document text for terms such as:
- berotralstat (and chemical/name variants)
- dosage, regimen, mg, administration schedule
- formulation terms (tablet/capsule/compound form, if claimed)
- “claims” section to read the numbered protections directly [1]
---
Sources
[1] https://patents.google.com/patent/US11117867B2/en